tiprankstipranks
Advertisement
Advertisement

INCY Stock Latest News

Incyte price target raised to $90 from $84 at Oppenheimer
The FlyIncyte price target raised to $90 from $84 at Oppenheimer
1d ago
INCY
Incyte price target raised to $123 from $120 at Stifel
PremiumThe Fly
Incyte price target raised to $123 from $120 at Stifel
1d ago
INCY
Incyte price target raised to $124 from $121 at BofA
PremiumThe Fly
Incyte price target raised to $124 from $121 at BofA
1d ago
INCY
Incyte: Buy Rating Reaffirmed as Pipeline Strength and Long-Term Visibility Drive Price Target Increase to $124
PremiumRatings
Incyte: Buy Rating Reaffirmed as Pipeline Strength and Long-Term Visibility Drive Price Target Increase to $124
1d ago
INCY
Incyte Earnings Call Highlights Broad Growth, Rising Risks
PremiumCompany Announcements
Incyte Earnings Call Highlights Broad Growth, Rising Risks
2d ago
INCY
Incyte sees FY26 revenue $4.77B-$4.94B, consensus $5.57B
PremiumThe FlyIncyte sees FY26 revenue $4.77B-$4.94B, consensus $5.57B
2d ago
INCY
Incyte appoints Suketu Upadhyay as CFO
Premium
The Fly
Incyte appoints Suketu Upadhyay as CFO
2d ago
INCY
Incyte reports Q1 EPS $1.81, consensus $1.34
Premium
The Fly
Incyte reports Q1 EPS $1.81, consensus $1.34
2d ago
INCY
INCY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
INCY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4d ago
INCY
Incyte, BNY Mellon, Quantum-Si, Jabil, Levi Shock
PremiumWeekend Updates
Incyte, BNY Mellon, Quantum-Si, Jabil, Levi Shock
5d ago
BK
JBL
Incyte to announce full results from Phase 3 tafasitamab study at ASCO
PremiumThe Fly
Incyte to announce full results from Phase 3 tafasitamab study at ASCO
9d ago
INCY
Bullish View on Povorcitinib’s Broad HS Adoption and Manageable JAK Safety Supports $135 Target
PremiumRatings
Bullish View on Povorcitinib’s Broad HS Adoption and Manageable JAK Safety Supports $135 Target
15d ago
INCY
Incyte price target raised to $95 from $92 at RBC Capital
PremiumThe FlyIncyte price target raised to $95 from $92 at RBC Capital
23d ago
INCY
Incyte Announces Upcoming Resignation of Board Member Schaffert
Premium
Company Announcements
Incyte Announces Upcoming Resignation of Board Member Schaffert
1M ago
8K
INCY
Incyte announces new 54-week data on safety, efficacy of povorcitinib
Premium
The Fly
Incyte announces new 54-week data on safety, efficacy of povorcitinib
1M ago
INCY
Incyte Announces Major Executive Leadership and Commercial Reorganization
PremiumCompany Announcements
Incyte Announces Major Executive Leadership and Commercial Reorganization
1M ago
8K
INCY
Incyte price target lowered to $94 from $104 at UBS
PremiumThe Fly
Incyte price target lowered to $94 from $104 at UBS
1M ago
INCY
Incyte appoints Stein as Chief Medical Officer, Issa as EVP
PremiumThe Fly
Incyte appoints Stein as Chief Medical Officer, Issa as EVP
1M ago
INCY
Incyte Expands Blood Cancer Pipeline With New Early Stage INCA036978 Trial
PremiumCompany Announcements
Incyte Expands Blood Cancer Pipeline With New Early Stage INCA036978 Trial
1M ago
INCY
Knight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
PremiumThe FlyKnight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
1M ago
INCY
Qualcomm, Adobe downgraded: Wall Street’s top analyst calls
Premium
The Fly
Qualcomm, Adobe downgraded: Wall Street’s top analyst calls
2M ago
ECL
ETN
Incyte downgraded to Hold from Buy at Jefferies
Premium
The Fly
Incyte downgraded to Hold from Buy at Jefferies
2M ago
INCY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >